Scholarlink

Background <p>This study evaluated the therapeutic effect of <i>Saccharomyces boulardii</i> in children with IBS-D, focusing on its mechanism of action associated with gut microbiota regulation and immune response.</p> Methods <p>A total of 60 children were randomly divided into <i>Saccharomyces boulardii</i> treatment group and placebo treatment group. Treatment continued for 14 days, during which the severity of IBS symptoms and associated biochemical markers were monitored. At the same time, the mechanism of action of <i>Saccharomyces boulardii</i> therapy was explored through animal experiments and microbial analysis.</p> Results <p>Clinical data have shown that <i>Saccharomyces boulardii</i> treatment significantly improves IBS-D symptoms in children, as evidenced by the reduction in IBS symptom severity scale score and normalization of stool morphology. Animal mechanistic studies have revealed the role of <i>Saccharomyces boulardii</i> in regulating gut microbiota diversity and reducing inflammatory markers.</p> Conclusion <p><i>Saccharomyces boulardii</i> shows potential as an effective probiotic supplement for treating pediatric IBS-D, providing benefits through modulation of gut microbiota and reduction of inflammation.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>This study investigated the efficacy and mechanism of <i>Saccharomyces boulardii</i> in the treatment of children with diarrheal irritable bowel syndrome (IBS-D) through clinical trials and animal models.</p> </ItemContent> <ItemContent> <p>The specific role of <i>Saccharomyces boulardii</i> in the treatment of IBS-D is described, supplementing the evidence in the existing literature. Through animal experiments and microbial analysis, its role in regulating intestinal microbiota and immune response was further elucidated.</p> </ItemContent> <ItemContent> <p>The results suggest that <i>Saccharomyces boulardii</i> can treat IBS-D in children, providing clinicians with new treatment options and stimulating more research into the role of probiotics in regulating gut health and immune response.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Saccharomyces boulardii’s impact on pediatric diarrhea-predominant irritable bowel syndrome: animal model findings

  • 期刊论文

  • 发表日期：

    2025年11月10日

查看全文
  • Xinyu Jin,
  • Piao Guo,
  • Xin Jin,
  • Wenjuan Xia,
  • Xinrong Liu,
  • Weisong Sheng,
  • Danrong Zhu

摘要

Background

This study evaluated the therapeutic effect of Saccharomyces boulardii in children with IBS-D, focusing on its mechanism of action associated with gut microbiota regulation and immune response.

Methods

A total of 60 children were randomly divided into Saccharomyces boulardii treatment group and placebo treatment group. Treatment continued for 14 days, during which the severity of IBS symptoms and associated biochemical markers were monitored. At the same time, the mechanism of action of Saccharomyces boulardii therapy was explored through animal experiments and microbial analysis.

Results

Clinical data have shown that Saccharomyces boulardii treatment significantly improves IBS-D symptoms in children, as evidenced by the reduction in IBS symptom severity scale score and normalization of stool morphology. Animal mechanistic studies have revealed the role of Saccharomyces boulardii in regulating gut microbiota diversity and reducing inflammatory markers.

Conclusion

Saccharomyces boulardii shows potential as an effective probiotic supplement for treating pediatric IBS-D, providing benefits through modulation of gut microbiota and reduction of inflammation.

Impact

This study investigated the efficacy and mechanism of Saccharomyces boulardii in the treatment of children with diarrheal irritable bowel syndrome (IBS-D) through clinical trials and animal models.

The specific role of Saccharomyces boulardii in the treatment of IBS-D is described, supplementing the evidence in the existing literature. Through animal experiments and microbial analysis, its role in regulating intestinal microbiota and immune response was further elucidated.

The results suggest that Saccharomyces boulardii can treat IBS-D in children, providing clinicians with new treatment options and stimulating more research into the role of probiotics in regulating gut health and immune response.